수술 및 항암 방사선 치료에 실패 후 표적 치료로 완전 관해를 유도한 비강 저분화형 암종 1예 = A Case of Complete Remission of Nasal Cavity Poorly Differentiated Carcinoma With Targeted Therapy, to Which Surgery and Concurrent Chemoradiotherapy Was Ineffective

다국어 초록 (Multilingual Abstract)

Nasal cavity and paranasal sinus cancers comprise about 1% of all malignancies, and 5% ofhead and neck malignancy. Squamous cell carcinoma comprises more than half of nasal cavi-ty cancers. Treatment is determined by considering tumor size, location, staging, age, generalcondition, purpose of treatment, etc. Conventional therapy includes surgery, radiotherapy, andchemotherapy; however, for the locally advanced, recurrent, or metastatic cancer after con-ventional therapy, immunotherapy or targeted therapy are taken into consideration. Targettherapy attacks specific cancer cells directly, such as cancer cells with certain gene mutation,whereas immunotherapy attacks cancer cells indirectly, stimulating our own immune system,such as T-cell activity. Histologically poorly differentiated carcinomas are treated with sur-gery, radiotherapy, and sometimes chemotherapy, but 5-year survival rate is low due to fre-quent recurrence. Here, we present a case of successful targeted therapy applied to recurrentnasal cavity cancer after serial application of conventional therapies.

참고문헌 (Reference)

1 Ackall FY, "Survival outcomes in sinonasal poorly differentiated squamous cell carcinoma" 131 (131): E1040-8, 2021

2 Bugra Cengiz A, "Sinonasal tract malignancies : Prognostic factors and surgery outcomes" 15 (15): e14118-, 2013

3 Bonner JA, "Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck" 354 (354): 567-578, 2006

4 Bonner JA, "Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival" 11 (11): 21-28, 2010

5 Vermorken JB, "Platinum-based chemotherapy plus cetuximab in head and neck cancer" 359 (359): 1116-1127, 2008

6 Glisson BS, "Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck" 20 (20): 1593-1599, 2002

7 Burtness B, "Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048):A randomised, open-label, phase 3 study" 394 (394): 1915-1928, 2019

8 Ferris RL, "Nivolumab for recurrent squamous-cell carcinoma of the head and neck" 375 (375): 1856-1867, 2016

9 McCormack PL, "Nintedanib : First global approval" 75 (75): 129-139, 2015

10 Kazi M, "Management of sinonasal tumors : Prognostic factors and outcomes : A 10 year experience at a tertiary care hospital" 65 (65): 155-159, 2013

11 Agarwal V, "Is EGFR really a therapeutic target in head and neck cancers?" 119 (119): 685-686, 2019

12 Sjöstedt S, "Incidence and survival in sinonasal carcinoma: A Danish population-based, nationwide study from 1980 to 2014" 57 (57): 1152-1158, 2018

13 Mei Z, "Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma" 12 (12): 16-, 2020

14 Kitamura N, "Current trends and future prospects of molecular targeted therapy in head and neck squamous cell carcinoma" 22 (22): 240-, 2020

15 Kim Y, "Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck : A multicenter phase 2 study(Korean Cancer Study Group HN14-01)" 123 (123): 1958-1964, 2017